Earnings Feed
Sign Up
Home/Filings/4/0001209191-19-038034
4//SEC Filing

D'Onofrio Matthew J 4

Accession 0001209191-19-038034

CIK 0001403708other
View on SEC.govCompany Profile

Filed

Jun 18, 8:00 PM ET

Accepted

Jun 19, 4:36 PM ET

Size

32.8 KB

Accession

0001209191-19-038034

Insider Transaction Report

Form 4
Period: 2019-06-17
Evoke Pharma IncEVOK
D'Onofrio Matthew J
Exec VP, Chief Bus. Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2019-06-17−48,750→ 48,750 total
    Exercise: $0.62Exp: 2026-01-27→ Common Stock (48,750 underlying)
  • Award

    Stock Option (Right to Buy)

    2019-06-17−39,375→ 39,375 total
    Exercise: $0.62Exp: 2026-02-04→ Common Stock (39,375 underlying)
  • Award

    Stock Option (Right to Buy)

    2019-06-17−112,500→ 112,500 total
    Exercise: $0.62Exp: 2028-02-06→ Common Stock (112,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-06-17+70,687→ 0 total
    Exercise: $3.04Exp: 2026-02-04→ Common Stock (70,687 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-06-17+150,000→ 0 total
    Exercise: $2.94Exp: 2029-02-05→ Common Stock (150,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-06-17+150,000→ 0 total
    Exercise: $2.36Exp: 2027-01-24→ Common Stock (150,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2019-06-17−112,500→ 112,500 total
    Exercise: $0.62Exp: 2017-01-24→ Common Stock (112,500 underlying)
  • Award

    Stock Option (Right to Buy)

    2019-06-17−112,500→ 112,500 total
    Exercise: $0.62Exp: 2029-02-05→ Common Stock (112,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-06-17+65,000→ 0 total
    Exercise: $3.07Exp: 2026-01-27→ Common Stock (65,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2019-06-17−53,015→ 53,015 total
    Exercise: $0.62Exp: 2026-02-04→ Common Stock (53,015 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-06-17+52,500→ 0 total
    Exercise: $3.04Exp: 2026-02-04→ Common Stock (52,500 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-06-17+150,000→ 0 total
    Exercise: $2.43Exp: 2028-02-06→ Common Stock (150,000 underlying)
Footnotes (12)
  • [F1]The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2016, subject to the reporting person's continued service to the Issuer through each such vesting date.
  • [F10]The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date.
  • [F11]On June 17, 2019, the Issuer canceled an option granted on February 6, 2019. In exchange for the canceled option, the reporting person received 112,500 options to purchase common stock.
  • [F12]The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on June 17, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date.
  • [F2]On June 17, 2019, the Issuer canceled an option granted on January 28, 2016. In exchange for the canceled option, the reporting person received 48,750 options to purchase common stock.
  • [F3]The total number of shares of common stock subject to the option vests in 36 equal monthly installments over the three-year period beginning on January 1, 2016, subject to the reporting person's continued service to the Issuer through each such vesting date.
  • [F4]On June 17, 2019, the Issuer canceled an option granted on February 5, 2016. In exchange for the canceled option, the reporting person received 53,015 options to purchase common stock.
  • [F5]On June 17, 2019, the Issuer canceled an option granted on February 5, 2016. In exchange for the canceled option, the reporting person received 39,375 options to purchase common stock.
  • [F6]The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2017, subject to the reporting person's continued service to the Issuer through each such vesting date.
  • [F7]On June 17, 2019, the Issuer canceled an option granted on January 25, 2017. In exchange for the canceled option, the reporting person received 112,500 options to purchase common stock.
  • [F8]The option grant date was February 7, 2018, subject to approval of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "Plan") by the Issuer's stockholders which occurred at the Issuer's annual stockholder meeting on April 26, 2018. The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2018, subject to the reporting person's continued service to the Issuer through each such vesting date. Notwithstanding the foregoing vesting schedule, in no event may the option be exercised prior to the earlier of (i) the date on which the Issuer receives marketing approval from the U.S. Food and Drug Administration of Gimoti, (ii) the second anniversary of the date of grant, or (iii) the date of a "change in control" under Section 2.9 of the Plan.
  • [F9]On June 17, 2019, the Issuer canceled an option granted on February 7, 2018. In exchange for the canceled option, the reporting person received 112,500 options to purchase common stock.

Documents

1 file

Issuer

Evoke Pharma Inc

CIK 0001403708

→
Entity typeother

Related Parties

1
  • filerCIK 0001578770

Filing Metadata

Form type
4
Filed
Jun 18, 8:00 PM ET
Accepted
Jun 19, 4:36 PM ET
Size
32.8 KB
View on SEC.gov